ORIGINAL RESEARCH article

Front. Med., 07 August 2024

Sec. Ophthalmology

Volume 11 - 2024 | https://doi.org/10.3389/fmed.2024.1410607

A study exploring the causal relationship between glaucoma and anxiety disorders

  • 1. Xiamen Eye Center and Eye Institute of Xiamen University, Xiamen, China

  • 2. Xiamen Clinical Research Center for Eye Diseases, Xiamen, Fujian, China

  • 3. Xiamen Key Laboratory of Ophthalmology, Xiamen, Fujian, China

  • 4. Fujian Key Laboratory of Corneal and Ocular Surface Diseases, Xiamen, Fujian, China

  • 5. Xiamen Key Laboratory of Corneal and Ocular Surface Diseases, Xiamen, Fujian, China

  • 6. Translational Medicine Institute of Xiamen Eye Center of Xiamen University, Xiamen, Fujian, China

Abstract

Background:

Glaucoma, a leading cause of global blindness, is characterized by optic nerve damage and visual field loss. Previous studies have suggested a potential association between glaucoma and anxiety disorders. However, the causal relationship between these two conditions remains unclear.

Methods:

In this study, we conducted a Mendelian Randomization analysis to investigate the causal relationship between glaucoma and anxiety disorders. We sourced Genome-Wide Association Study (GWAS) datasets for glaucoma and anxiety with the largest sample sizes from the Integrative Epidemiology Unit OpenGWAS (IEU OpenGWAS) project website. Instrumental variables were selected based on specific criteria, and statistical analyses were performed using the R programming language.

Results:

After filtering and merging the datasets, a total of 60 Single Nucleotide Polymorphisms (SNPs) were obtained for analysis. Regression models were applied to assess the causal relationship between glaucoma and anxiety disorders. The results from all four methods indicated that glaucoma does not cause anxiety disorders (p > 0.05).

Conclusion:

Through rigorous Mendelian Randomization analysis, our findings indicate that glaucoma is not a causative factor for anxiety, with minimal influence from confounding factors in this study. These findings enhance our understanding of the relationship between glaucoma and anxiety.

1 Background

Glaucoma, a leading cause of global blindness, is characterized by optic nerve damage and visual field loss, often culminating in blindness (1). With multifactorial etiology, it affects approximately 5.2 million individuals worldwide, constituting 15% of the global burden of blindness (2). Moreover, due to population aging, its prevalence is expected to rise, projected to affect approximately 112 million people by 2040 (3).

Anxiety disorders represent the most prevalent mental health issues globally, significantly impacting individuals’ quality of life, work productivity, and societal well-being. Despite being distinct diagnostic entities, anxiety often coexist clinically, demonstrating high comorbidity (4). Globally, it is estimated that 3.7% of individuals will experience Generalized Anxiety Disorder (GAD) at some point in their lives (5). The impact of GAD on functioning and quality of life is comparable to, or even greater than, the effects associated with severe depression and substance abuse disorders (6).

In recent years, increasing attention has been directed toward the high prevalence of anxiety among individuals with glaucoma. These studies suggest that glaucoma is not solely a visually impairing ocular condition but may also be linked to patients’ psychological well-being, indicating a close interplay between the two (710).

In our research, we employed the two-sample Mendelian Randomization (MR) approach, leveraging Single Nucleotide Polymorphisms (SNPs) as instrumental variables derived from Genome-Wide Association Study (GWAS) summary statistics. This methodology was utilized to explore the potential causal linkage between Glaucoma and Anxiety. By conducting this gene-centric analysis, our goal was to surpass the constraints associated with conventional research methodologies, thereby furnishing more robust evidence in favor of a causal connection between Glaucoma and anxiety, as depicted in Figure 1.

FIGURE 1

2 Materials and methods

We conducted a Mendelian Randomization investigation to elucidate the potential causal association between Glaucoma and the susceptibility to anxiety. The MR methodology employs genetic variants as instrumental variables to estimate the causal impact of the exposure (Glaucoma) on the outcome (risk of anxiety), while mitigating the influence of confounding factors. All statistical analyses were executed using the R programming language, employing specialized software packages tailored for MR studies such as TwoSampleMR and Mendelian Randomization.

2.1 Data source

We sourced GWAS datasets for Glaucoma (Pubmed ID: GCST90011766) and anxiety (Pubmed ID: GCST007710) with the largest sample sizes from the Integrative Epidemiology Unit OpenGWAS (IEU OpenGWAS) project website.1 Raw data can be accessed via the respective publications on the Pubmed website. Data retrieval occurred on March 21, 2024. Both datasets comprised European populations without gender restrictions. The Glaucoma dataset encompassed 14,219,919 SNPs, while the anxiety dataset comprised 18,485,882 SNPs.

2.2 Instrumental variable criteria

Criteria for selecting SNPs as instrumental variables were as follows:

  • (1)

    The instrumental variables exhibited high correlation with the exposure, with an F-statistic exceeding 10 indicating substantial correlation (11).

  • (2)

    Instrumental variables were not directly associated with the outcome but influenced it solely through the exposure, indicating absence of genetic pleiotropy. A pleiotropy test was conducted, with a result of P ≥ 0.05 signifying no genetic pleiotropy.

  • (3)

    Instrumental variables were unrelated to unmeasured confounding factors. Since MR-selected SNPs adhere to the genetic principle of random allele allocation from parents to offspring, their susceptibility to environmental and postnatal factors is minimal. Thus, it was theoretically assumed that instrumental variables remained independent of environmental factors such as socioeconomic and cultural influences (12).

2.3 SNP selection

Meaningful SNPs were selected from the GWAS summary data of Glaucoma based on a screening criterion of P < 5 × 10–8. Each SNP’s independence was ensured by setting a linkage disequilibrium coefficient (r2) of 0.001 and a linkage disequilibrium region width of 10,000 kb, thereby mitigating the potential influence of genetic pleiotropy (13). Glaucoma-associated SNPs were then extracted from the anxiety GWAS summary data, with a minimum r2 > 0.8 to ensure result accuracy. Missing SNPs were directly excluded. The datasets were integrated, and SNPs directly associated with anxiety (P < 5 × 10–8) were filtered out.

2.4 Causal relationship verification

To verify the causal relationship between Glaucoma exposure and anxiety outcome using SNPs as instrumental variables, we employed four regression models: MR-Egger regression, weighted median estimator (WME), inverse-variance weighted (IVW) random-effects model, and simple model. The IVW method directly calculates causal effect estimates using summary data, without the need for individual-level data. MR-Egger regression fits a linear function by assessing the correlation between each SNP and anxiety (Y) and between each SNP and Glaucoma (X). Sensitivity analysis utilized the leave-one-out method. All analyses were conducted using the TwoSampleMR package (version 0.5.11) in R Studio software (version 4.3.3), with a significance level of α = 0.05.

3 Results

3.1 SNP information screening results

A total of 14,219,919 SNP information was obtained for Glaucoma. After filtering based on a criterion of P-value < 5 × 10–8, 4,358 SNPs remained. The file “exposure_GLA.csv” was exported and placed in the TwoSampleMR folder. After renaming the sequence names, SNPs were selected to ensure independence by setting a linkage disequilibrium coefficient (r2) of 0.001 and a linkage disequilibrium region width of 10,000 kb, excluding the influence of genetic pleiotropy. This resulted in the removal of 4,297 SNPs, leaving 61 SNP data. At this time, the SNP database of anxiety was imported, and the number of SNPs obtained was 18,485,882. Then, the anxiety data and Glaucoma data which just screened were merged, and 60 SNPs were finally obtained (Table 1). Heterogeneity test was carried out on these 60 SNP data, and three sets of outlier data were found, namely data No. 17, 45, and 49. No significant changes were found when they were removed. According to MR Egger regression model, p = 0.56, IVW regression model, p = 0.56, both of which are greater than 0.05, suggesting that glaucoma does not cause anxiety disorder.

TABLE 1

NumberSNPCHRBPA1BetaSE
1rs101512201434715465T−0.00190.0015
2rs102309417117636111C0.00130.0015
3rs10248136739077397T−0.00220.0015
4rs10517281454027595A9.00E−040.0015
5rs107396899129914147C6.00E−040.0015
6rs1114390951376254433A0.00140.0015
7rs11397952219867771T0.00130.0016
8rs116583341758830188A6.00E−040.0017
9rs119688836158971411T0.00220.0015
10rs12208086636586070A−0.00260.0015
11rs125400357116159526A−0.0040.0015
12rs13369809129377855C3.00E−040.0015
13rs16490681060304864A0.00360.0015
14rs171259731453415359A0.00140.0015
15rs175270164111963719T−4.00E−040.0015
16rs1972459783287607A−0.00210.0015
17rs2113818212890860T−0.00160.0015
18rs24724949107695539T−0.00220.0015
19rs25148858108277130T0.00140.0015
20rs2573361665055840T0.00540.0015
21rs2579989651460154T00.0015
22rs2627761255933014T8.00E−040.0016
23rs26674771284023388T0.00220.0015
24rs2735114629910034A0.0010.0015
25rs274557261548369A0.00180.0015
26rs27900491165743523A0.00180.0015
27rs28116886134372150C−6.00E−040.0015
28rs31916514814883A0.00240.0015
29rs339123451460976537A9.00E−040.0016
30rs36039219711704538A2.00E−040.0015
31rs37538411103379918A0.00310.0015
32rs38259421574219582A−0.00260.0016
33rs412836941060156574A0.00290.0016
34rs415433171744087500A−8.00E−040.0015
35rs4414666266537344T00.0015
36rs4577906782955177C0.00350.0015
37rs4652964138078300A0.00120.0015
38rs4653159136579215A0.00220.0015
39rs48196412218353630C0.00140.0015
40rs558822522153361700T00.0015
41rs562334263186128816A−0.00280.0015
42rs5807304611120248493A−0.00110.0015
43rs5817961186355565T0.0030.0015
44rs6117318206507717A−9.00E−040.0015
45rs622838093171820211T−0.00150.0017
46rs6475604922052734T8.00E−040.0015
47rs64906971322679011T−0.00170.0016
48rs66024531010840849A−1.00E−040.0015
49rs67601562064648T−7.00E−040.0015
50rs684565347899379T0.00320.0015
51rs713782812111932800T−0.00640.0015
52rs724828501101117684A4.00E−040.0015
53rs72751182018010447T−5.00E−040.0015
54rs72842452229613441T−4.00E−040.0016
55rs794600911128387422T−0.00370.0015
56rs79728741228203245A−3.00E−040.0015
57rs9353281557538801A−0.00220.0015
58rs94944576136474794A−4.00E−040.0015
59rs9819278385144350A−0.00520.0015
60rs99139111710031183A1.00E−040.0015

Summary of the selected SNP information.

SNP, SNP number; CHR, chromosome number; BP: location, A1: effector allele.

3.2 Causal relationship verification

The regression results of the four methods are shown in Table 2. And all the calculation result of the regression models are greater than 0.05. So this Mendelian randomization study tells us that glaucoma patients do not have a higher incidence of anxiety. The scatter plot is shown in Figure 2.

TABLE 2

Four methods MR regression model results
MethodβseOR (95% CI)P
MR-Egger0.0030.0061.004(0.991∼1.016)0.563
WME0.0000.0031.000(0.995∼1.005)1.000
IVW0.0020.0030.998 (0.993∼1.004)0.556
Simple mode0.0020.0061.002 (0.992∼1.013)0.725

Regression model results of the four methods.

WME, weighted median estimator; IVW, inverse-variance weighted.

FIGURE 2

3.3 Sensitivity analysis

The sensitivity analysis was performed using the leave-one-out method, and the results showed that regardless of which SNP was removed, the conclusions have not changed. This suggests that removing any individual SNP would not have a significant impact on the results, indicating the robustness of the MR findings in this study. The funnel plot and detailed sensitivity analysis results can be found in Figures 3, 4, respectively.

FIGURE 3

FIGURE 4

4 Discussion

Glaucoma is characterized by optic neuropathy with a hallmark of progressive loss of retinal ganglion cells (14). Currently, there are no effective treatments for the degeneration of these cells, and the primary goal of glaucoma management is to reduce the intraocular pressure (15) and prevent progression (16). Particularly since intraocular pressure is the only treatable risk factor (17) in clinical practice, both doctors and patients give it special attention, making it a chronic condition that requires lifelong care (18). However, chronic illnesses are often associated with psychological disorders such as anxiety (19, 20). Agorastos et al. (21) found that among glaucoma patients, the prevalence of anxiety in those with visual field defects was 44.8%, compared to 24.3% in those without visual field defects (21). However, DY Shin et al. found that patients with anxiety showed faster rates of Retinal Nerve Fiber Layer (RNFL) decline, as measured by Optical Coherence Tomography (OCT) (10).

There is a substantial body of research indicating high prevalence rates of anxiety among glaucoma patients (22, 23). These studies suggest that the heightened incidence of anxiety may stem from the diagnosis of glaucoma itself, driven by concerns over potential blindness, the financial burdens of treatment, and impaired daily activities (24, 25). Anxiety, as stress responses, are thought to originate in the amygdala (26), eliciting neurotransmitter release and stimulating the autonomic nervous system (ANS), which impacts multiple organs (27). The ANS’s response to emotional stress may play a significant role in the development or progression of glaucoma (28, 29). Furthermore, excessive retinal oxidative stress in glaucoma, leading to widespread loss of melanopsin-expressing retinal ganglion cells, plays a critical role in non-visual phototransduction, affecting circadian rhythm changes and melatonin production indirectly (30, 31). Additionally, some glaucoma medications may alter patients’ mood (32).

Despite the abundance of studies indicating a link between glaucoma and increased rates of anxiety, contrasting research from various global scholars suggests that glaucoma patients do not exhibit a heightened probability of suffering from these mental health conditions (3335). All these clinical investigations have yet to definitively establish the causal relationship between glaucoma and anxiety.

Traditional epidemiological studies are hindered by confounding factors and reverse causality, complicating the determination of the true causal relationship between glaucoma and mental health issues. In this context, MR offers a unique approach, utilizing genetic variants as instrumental variables to estimate the causal effect of one factor on another, circumventing the limitations inherent in the aforementioned study designs (36).

Therefore, we decided to further explore the relationship between glaucoma and anxiety disorders using MR studies. Our findings across various models, including MR Egger regression, Inverse Variance Weighted (IVW) regression, and Weighted Median regression models, indicate that glaucoma does not cause anxiety disorders, with p-values of 0.56 for both MR Egger and IVW models, exceeding the threshold of 0.05. Even after excluding three outliers, the conclusion remained unchanged, and sensitivity analyses confirmed the stability of this conclusion. Pleiotropy analysis yielded a p-value of 0.38, suggesting that the trial results are reliable and not overly influenced by confounding factors. Additionally, the intercept of the MR-Egger regression line with the y-axis being less than 0.001 in Figure 2 also indicates a low likelihood of confounding factors. These MR study results suggest that there is no direct causal link between glaucoma and anxiety, and there are no significant confounding factors at the genetic level. It should be noted that even among Asians, studies have shown significant variability in the prevalence of anxiety among patients with glaucoma. Specifically, the prevalence of anxiety in Japanese glaucoma patients is 13.0% (8), while in Chinese patients, it is 22.9% (37). Notably, the prevalence in Singaporean glaucoma patients reaches as high as 64% (38). Scholars have found that these studies differ in terms of research design, sample size, and demographic characteristics (24). These findings contribute to a better understanding of the relationship between glaucoma and anxiety.

The availability of GWAS data for East Asian and African populations is limited. Although we found an East Asian Glaucoma SNP database through the IEU OpenGWAS project website (PubMed ID: GCST005388), a reliable database related to anxiety in the East Asian population was not found. To ensure the accuracy of our experimental results, we ultimately opted to use a European database. This decision also facilitates future comparisons with research conducted by other scholars. Finally, while this study explored the genetic association between glaucoma and anxiety within a European population database, it holds implications for the prevention and treatment of anxiety caused by glaucoma in other populations and nations. However, we must acknowledge that the lack of analysis of other ethnic groups represents a significant limitation of our research.

It is important to note that this study does not completely exclude the relationship between elevated intraocular pressure and anxiety. This indeed presents an interesting direction for research, which could further elucidate the interpretation of our results. We hope that our team can present findings in this area shortly.

5 Conclusion

Through rigorous Mendelian Randomization analysis, our findings indicate that glaucoma is not a causative factor for anxiety, with minimal influence from confounding factors in this study. These findings enhance our understanding of the relationship between glaucoma and anxiety.

Statements

Data availability statement

The original contributions presented in this study are included in the article/supplementary material, further inquiries can be directed to the corresponding author.

Author contributions

BL: Data curation, Formal analysis, Methodology, Software, Writing – original draft, Writing – review and editing. MX: Data curation, Formal analysis, Methodology, Writing – original draft. L-lC: Data curation, Formal analysis, Funding acquisition, Writing – original draft. D-kL: Funding acquisition, Supervision, Writing – review and editing.

Funding

The author(s) declare that financial support was received for the research, authorship, and/or publication of this article. This study was supported by the Xiamen Municipal Bureau of Science and Technology (3502Z202374104).

Acknowledgments

We thank Jing Tang for their help in data collection in this study.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

References

  • 1.

    StamatiouMKazantzisDTheodossiadisPChatziralliI. Depression in glaucoma patients: A review of the literature.Semin Ophthalmol. (2022) 37:2935. 10.1080/08820538.2021.1903945

  • 2.

    ThyleforsBNegrelA. The global impact of glaucoma.Bull World Health Organ. (1994) 72:323.

  • 3.

    ThamYLiXWongTQuigleyHAungTChengC. Global prevalence of glaucoma and projections of glaucoma burden through 2040: A systematic review and meta-analysis.Ophthalmology. (2014) 121:208190. 10.1016/j.ophtha.2014.05.013

  • 4.

    TillerJ. Depression and anxiety.Med J Aust. (2013) 199:S2831. 10.5694/mjao12.10628

  • 5.

    RuscioAHallionLLimCAguilar-GaxiolaSAl-HamzawiAAlonsoJet alCross-sectional comparison of the epidemiology of DSM-5 generalized anxiety disorder across the globe.JAMA Psychiatry. (2017) 74:46575. 10.1001/jamapsychiatry.2017.0056

  • 6.

    HoffmanDDukesEWittchenH. Human and economic burden of generalized anxiety disorder.Depress Anxiety. (2008) 25:7290. 10.1002/da.20257

  • 7.

    CumurcuTCumurcuBCelikelFEtikanI. Depression and anxiety in patients with pseudoexfoliative glaucoma.Gen Hosp Psychiatry. (2006) 28:50915. 10.1016/j.genhosppsych.2006.09.004

  • 8.

    MabuchiFYoshimuraKKashiwagiKShioeKYamagataZKanbaSet alHigh prevalence of anxiety and depression in patients with primary open-angle glaucoma.J Glaucoma. (2008) 17:5527. 10.1097/IJG.0b013e31816299d4

  • 9.

    SkalickySGoldbergI. Depression and quality of life in patients with glaucoma: A cross-sectional analysis using the geriatric depression scale-15, assessment of function related to vision, and the glaucoma quality of life-15.J Glaucoma. (2008) 17:54651. 10.1097/IJG.0b013e318163bdd1

  • 10.

    ShinDJungKParkHParkC. The effect of anxiety and depression on progression of glaucoma.Sci Rep. (2021) 11:1769. 10.1038/s41598-021-81512-0

  • 11.

    BoggsJBeckARitzwollerDBattagliaCAndersonHLindroothR. A quasi-experimental analysis of lethal means assessment and risk for subsequent suicide attempts and deaths.J Gen Intern Med. (2020) 35:170914. 10.1007/s11606-020-05641-4

  • 12.

    SandersonEGlymourMHolmesMKangHMorrisonJMunafòMet alMendelian randomization.Nat Rev Methods Prim. (2022) 2:6. 10.1038/s43586-021-00092-5

  • 13.

    HemaniGZhengJElsworthBWadeKHaberlandVBairdDet alThe MR-Base platform supports systematic causal inference across the human phenome.Elife. (2018) 7:e34408. 10.7554/eLife.34408

  • 14.

    WeinrebRAungTMedeirosF. The pathophysiology and treatment of glaucoma: A review.JAMA. (2014) 311:190111. 10.1001/jama.2014.3192

  • 15.

    HeijlALeskeMBengtssonBHymanLBengtssonBHusseinMet alReduction of intraocular pressure and glaucoma progression: Results from the early manifest glaucoma trial.Arch Ophthalmol. (2002) 120:126879. 10.1001/archopht.120.10.1268

  • 16.

    KhatibTMartinK. Protecting retinal ganglion cells.Eye. (2017) 31:21824. 10.1038/eye.2016.299

  • 17.

    De BernardoMCasaburiCDe PascaleICapassoLCioneFRosaN. Comparison between dynamic contour tonometry and Goldmann applanation tonometry correcting equations.Sci Rep. (2022) 12:20190. 10.1038/s41598-022-24318-y

  • 18.

    JindalV. Glaucoma: An extension of various chronic neurodegenerative disorders.Mol Neurobiol. (2013) 48:1869. 10.1007/s12035-013-8416-8

  • 19.

    ClarkeDCurrieK. Depression, anxiety and their relationship with chronic diseases: A review of the epidemiology, risk and treatment evidence.Med J Aust. (2009) 190:S5460. 10.5694/j.1326-5377.2009.tb02471.x

  • 20.

    MoussaviSChatterjiSVerdesETandonAPatelVUstunB. Depression, chronic diseases, and decrements in health: Results from the world health surveys.Lancet. (2007) 370:8518. 10.1016/S0140-6736(07)61415-9

  • 21.

    AgorastosASkevasCMatthaeiMOtteCKlemmMRichardGet alDepression, anxiety, and disturbed sleep in glaucoma.J Neuropsychiatry Clin Neurosci. (2013) 25:20513. 10.1176/appi.neuropsych.12020030

  • 22.

    ZhangXOlsonDLePLinFFleischmanDDavisR. The association between glaucoma, anxiety, and depression in a large population.Am J Ophthalmol. (2017) 183:3741. 10.1016/j.ajo.2017.07.021

  • 23.

    WangSSinghKLinS. Prevalence and predictors of depression among participants with glaucoma in a nationally representative population sample.Am J Ophthalmol. (2012) 154:436444.e432. 10.1016/j.ajo.2012.03.039

  • 24.

    RezapourJNickelsSSchusterAMichalMMünzelTWildPet alPrevalence of depression and anxiety among participants with glaucoma in a population-based cohort study: The Gutenberg health study.BMC Ophthalmol. (2018) 18:157. 10.1186/s12886-018-0831-1

  • 25.

    GelderMGathDMayouR.Oxford textbook of psychiatry.Oxford: Oxford university press (1989).

  • 26.

    MartinEResslerKBinderENemeroffC. The neurobiology of anxiety disorders: Brain imaging, genetics, and psychoneuroendocrinology.Psychiatr Clin. (2009) 32:54975. 10.1016/j.psc.2009.05.004

  • 27.

    Hoehn-SaricRMcLeodDFunderburkFKowalskiP. Somatic symptoms and physiologic responses in generalized anxiety disorderand panic disorder: An ambulatory monitor study.Arch Gen Psychiatry. (2004) 61:91321. 10.1001/archpsyc.61.9.913

  • 28.

    ShinDJeonSParkHParkC. Posterior scleral deformation and autonomic dysfunction in normal tension glaucoma.Sci Rep. (2020) 10:8203. 10.1038/s41598-020-65037-6

  • 29.

    ParkHJungSParkSParkC. Detecting autonomic dysfunction in patients with glaucoma using dynamic pupillometry.Medicine. (2019) 98:e14658. 10.1097/MD.0000000000014658

  • 30.

    Jean-LouisGZiziFLazzaroDWolintzA. Circadian rhythm dysfunction in glaucoma: A hypothesis.J Circadian Rhyth. (2008) 6:1. 10.1186/1740-3391-6-1

  • 31.

    DrouyerEDkhissi-BenyahyaOChiquetCWoldeMussieERuizGWheelerLet alGlaucoma alters the circadian timing system.PLoS One. (2008) 3:e3931. 10.1371/journal.pone.0003931

  • 32.

    WeidenthalD. Charles Bonnet syndrome precipitated by brimonidine tartrate eye drops.J Pediatr. (2001) 138:4413.

  • 33.

    EramudugollaRWoodJAnsteyK. Co-morbidity of depression and anxiety in common age-related eye diseases: A population-based study of 662 adults.Front Aging Neurosci. (2013) 5:56. 10.3389/fnagi.2013.00056

  • 34.

    JonasJWeiWXuLRietschelMStreitFWangY. Self-rated depression and eye diseases: The Beijing eye study.PLoS One. (2018) 13:e0202132. 10.1371/journal.pone.0202132

  • 35.

    WeissGGoldichYBartovEBurgansky-EliashZ. Compliance with eye care in glaucoma patients with comorbid depression.IMAJ Israel Med Assoc J. (2011) 13:730.

  • 36.

    RichmondRSmithG. Mendelian randomization: Concepts and scope.Cold Spring Harb Perspect Med. (2022) 12:a040501. 10.1101/cshperspect.a040501

  • 37.

    ZhouCQianSWuPQiuC. Anxiety and depression in Chinese patients with glaucoma: Sociodemographic, clinical, and self-reported correlates.J Psychosom Res. (2013) 75:7582. 10.1016/j.jpsychores.2013.03.005

  • 38.

    LimNFanCYongMWongEYipL. Assessment of depression, anxiety, and quality of life in Singaporean patients with glaucoma.J Glaucoma. (2016) 25:60512. 10.1097/IJG.0000000000000393

Summary

Keywords

glaucoma, anxiety disorders, causal relationship, Mendelian Randomization, GWAS datasets

Citation

Lin B, Xu M, Chen L and Li D (2024) A study exploring the causal relationship between glaucoma and anxiety disorders. Front. Med. 11:1410607. doi: 10.3389/fmed.2024.1410607

Received

01 April 2024

Accepted

29 July 2024

Published

07 August 2024

Volume

11 - 2024

Edited by

Alessio Martucci, University of Rome Tor Vergata, Italy

Reviewed by

Ferdinando Cione, University of Salerno, Italy

Vanja Kopilaš, University of Zagreb, Croatia

Updates

Copyright

*Correspondence: Dong-kan Li,

†These authors have contributed equally to this work and share first authorship

Disclaimer

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Outline

Figures

Cite article

Copy to clipboard


Export citation file


Share article

Article metrics